Hillman Capital Management, Inc. — GSK PLC GSK: Quarterly 13F Position History
Hillman Capital Management, Inc. has reported GSK PLC (GSK) on 15 13F-HR filings in Pactolio's tracked window, first appearing in Q3 2022. As of Q1 2026, the position is sized at 97,432 shares ($5.4M market value, 3.73% of the equity book). Quarter-over-quarter share count change: 16,904 (-14.8%) .
- 97,432Shares Held (Latest Filing)
- $5.4MReported Market Value (Latest Filing)
- 3.73%Portfolio Weight (% of 13F Equity Book)
- 16,904Quarter-over-Quarter Share Change
- -$229.8KQuarter-over-Quarter Value Change
- 243,978Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 15 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 97,432 | 16,904 | -14.8% | $5.4M | 3.73% | $55.19 |
| Q4 2025 | 114,336 | 27,443 | -19.4% | $5.6M | 3.53% | $49.04 |
| Q3 2025 | 141,779 | 10,820 | -7.1% | $6.1M | 3.56% | $43.16 |
| Q2 2025 | 152,599 | 12,544 | -7.6% | $5.9M | 3.20% | $38.40 |
| Q1 2025 | 165,143 | 66,008 | -28.6% | $6.4M | 3.15% | $38.74 |
| Q4 2024 | 231,151 | +34,255 | +17.4% | $7.8M | 2.90% | $33.82 |
| Q3 2024 | 196,896 | +1,770 | +0.9% | $8.0M | 2.76% | $40.88 |
| Q2 2024 | 195,126 | 38,360 | -16.4% | $7.5M | 2.65% | $38.50 |
| Q1 2024 | 233,486 | +100 | +0.0% | $10.0M | 3.22% | $42.87 |
| Q4 2023 | 233,386 | +522 | +0.2% | $8.6M | 2.99% | $37.06 |
| Q3 2023 | 232,864 | 1,817 | -0.8% | $8.4M | 3.25% | $36.25 |
| Q2 2023 | 234,681 | 2,735 | -1.2% | $8.4M | 2.95% | $35.64 |
| Q1 2023 | 237,416 | 463 | -0.2% | $8.4M | 3.20% | $35.58 |
| Q4 2022 | 237,879 | 6,099 | -2.5% | $8.4M | 3.28% | $35.14 |
| Q3 2022 | 243,978 | — | — | $7.2M | 2.98% | $29.43 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Hillman Capital Management, Inc. first disclose a GSK position in 13F-HR filings?
Hillman Capital Management, Inc. first reported GSK PLC (GSK) on its 13F-HR filing for the period ending 2022-09-30 (Q3 2022). The position has appeared on 15 reported quarters within Pactolio's tracked window.
What was Hillman Capital Management, Inc.'s most recent quarter-over-quarter share-count change in GSK?
Between Q4 2025 and Q1 2026, Hillman Capital Management, Inc. reduced its GSK position by 16,904 shares (-14.8%), leaving 97,432 shares at a market value of $5.4M.
Does the implied price-per-share represent Hillman Capital Management, Inc.'s cost basis in GSK?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.